Ss 31: Chemical Properties
17 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: abril de 2026
Propiedades Químicas
| Molecular Formula | C₃₂H₄₉N₉O₅ (base libre) |
| Molecular Weight | 639,8 g/mol (base libre); 749,2 g/mol (sal de HCl) |
| CAS Number | 736992-21-5 (base libre); 72244098-12-0 (sal de HCl) |
| PubChem CID | 11764719 |
| Sequence (3-Letter) | D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimetiltirosina) |
| InChI Key | SFVLTCAESLKEHH-WKAQUBQDSA-N |
| Structure | Tetrapéptido lineal; D-aminoácido (D-Arg), aminoácido no natural (Dmt), amida C-terminal |
| Net Charge | 3+ a pH fisiológico |
| Alternating Motif | Aromático-catiónico (Dmt/Phe = aromático; D-Arg/Lys = catiónico) |
| Synonyms | Elamipretide, Forzinity™, MTP-131, Bendavia, RX-31 |
| Bioavailability (SC) | ~92–100% en humanos |
| Half-Life | ~3–4 horas (SC, humanos); ~1–2 horas (roedores) |
Identificadores
| Purity Standard | ≥98% por RP-HPLC |
| Identity Confirmation | Masa molecular por MS ~639,8 Da; LC-MS/MS para cuantificación en plasma (LLOQ 0,1 ng/mL) |
| Counter-Ion | Acetato o HCl (HCl = Forzinity comercial; acetato = desarrollo clínico) |
| Detection Methods | RP-HPLC, LC-MS/MS, ELISA |
| Metabolism | Proteólisis C-terminal → M1 (tripéptido) + M2 (dipéptido); NO es sustrato de CYP450 |
| Excretion | ~100% urinaria (compuesto original + metabolitos) |
Referencias
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.
- Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. JASN. 2013;24(8):1250-1261.
- FDA Press Announcement. FDA approves first treatment for rare genetic heart muscle disease. September 19, 2025.
- Campbell MD, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. 2019;134:268-281.
- Sabbah HN. Elamipretide (SS-31) improves mitochondrial function. Expert Opinion on Investigational Drugs. 2021;30(12):1227-1244.
- Sabbah HN, et al. Chronic therapy with elamipretide improves LV and mitochondrial function in dogs with advanced HF. Circ Heart Fail. 2016;9(2):e002206.
- Sabbah HN, et al. Elamipretide and NF-κB/NLRP3 inflammasome inhibition. Biomedicine & Pharmacotherapy. 2025;183:118056.
- Zhao W, et al. Elamipretide improves mitochondrial dysfunction, synaptic integrity, and cognition in AD model. Sci Rep. 2019;9(1):13137.
- Thompson WR, et al. Phase 2/3 RCT of elamipretide in Barth syndrome. Genetics in Medicine. 2024;101138.
- Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with PMM. Neurology. 2018;90(14):e1212-e1221.
- Birk AV, et al. Targeting mitochondrial cardiolipin and cytochrome c/cardiolipin complex. Br J Pharmacol. 2014;171(8):2017-2028.
- Cousins D, et al. Phase 2 study of elamipretide in AMD (ReCLAIM-2). Ophthalmology Retina. 2023.
- Saad A, et al. Phase 2a clinical trial of elamipretide during stent revascularization in ARAS. Circ Cardiovasc Interv. 2017;10(9):e005130.
- Dai DF, et al. Global proteomics of pressure-overload HF and attenuation by mitochondrial peptides. Circ Heart Fail. 2013;6(5):1067-1076.
- Chiao YA, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020;9:e55513.
- Lincoff AM, et al. Elamipretide and post-cardiac arrest outcomes (EMBRACE STEMI). Am Heart J. 2014;168(2):222-228.
- FDA Integrated Review NDA 215244 — Forzinity (elamipretide) Approval Package. 2025.
Preguntas de Investigación Relacionadas
Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de Ss 31→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.